Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 27, 2023

SELL
$5.9 - $6.95 $27,853 - $32,810
-4,721 Reduced 11.93%
34,852 $230,000
Q1 2023

Apr 27, 2023

SELL
$6.18 - $7.99 $2,107 - $2,724
-341 Reduced 0.85%
39,573 $269,000
Q3 2022

Oct 28, 2022

BUY
$9.44 - $11.76 $55,290 - $68,878
5,857 Added 17.2%
39,914 $394,000
Q2 2022

Aug 01, 2022

BUY
$9.31 - $11.84 $931 - $1,184
100 Added 0.29%
34,057 $371,000
Q1 2022

Apr 27, 2022

SELL
$10.84 - $16.55 $13,983 - $21,349
-1,290 Reduced 3.66%
33,957 $384,000
Q4 2021

Jan 24, 2022

BUY
$15.69 - $21.14 $22,279 - $30,018
1,420 Added 4.2%
35,247 $553,000
Q3 2021

Oct 25, 2021

SELL
$15.35 - $21.27 $2,041 - $2,828
-133 Reduced 0.39%
33,827 $580,000
Q1 2021

Apr 22, 2021

SELL
$13.42 - $20.28 $49,103 - $74,204
-3,659 Reduced 9.73%
33,960 $510,000
Q4 2020

Jan 25, 2021

SELL
$9.77 - $13.81 $977 - $1,381
-100 Reduced 0.27%
37,619 $494,000
Q3 2020

Nov 06, 2020

SELL
$9.32 - $12.02 $17,708 - $22,838
-1,900 Reduced 4.8%
37,719 $0
Q2 2020

Jul 21, 2020

BUY
$9.66 - $12.02 $966 - $1,202
100 Added 0.25%
39,619 $453,000
Q1 2020

Apr 29, 2020

SELL
$7.5 - $16.8 $2,250 - $5,040
-300 Reduced 0.75%
39,519 $409,000
Q4 2019

Jan 24, 2020

BUY
$12.38 - $17.47 $179,510 - $253,314
14,500 Added 57.27%
39,819 $653,000
Q3 2019

Oct 24, 2019

SELL
$12.27 - $15.79 $53,791 - $69,223
-4,384 Reduced 14.76%
25,319 $336,000
Q2 2019

Jul 18, 2019

SELL
$13.37 - $18.85 $38,773 - $54,665
-2,900 Reduced 8.89%
29,703 $419,000
Q1 2019

May 07, 2019

BUY
$17.59 - $31.05 $194,088 - $342,605
11,034 Added 51.16%
32,603 $600,000
Q4 2018

Jan 28, 2019

BUY
$18.97 - $31.47 $21,265 - $35,277
1,121 Added 5.48%
21,569 $564,000
Q3 2018

Nov 02, 2018

BUY
$18.25 - $23.0 $373,176 - $470,304
20,448 New
20,448 $469,000

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $274M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track New York State Teachers Retirement System Portfolio

Follow New York State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on New York State Teachers Retirement System with notifications on news.